BR122019026188A8 - Métodos para determinar se um indivíduo tem doença hepática gordurosa não alcoólica (nafld), se um indivíduo com esteatose não alcoólica tem esteato-hepatite não alcoólica e para monitorar um indivíduo com esteatose não alcoólica para o desenvolvimento de nash - Google Patents

Métodos para determinar se um indivíduo tem doença hepática gordurosa não alcoólica (nafld), se um indivíduo com esteatose não alcoólica tem esteato-hepatite não alcoólica e para monitorar um indivíduo com esteatose não alcoólica para o desenvolvimento de nash

Info

Publication number
BR122019026188A8
BR122019026188A8 BR122019026188A BR122019026188A BR122019026188A8 BR 122019026188 A8 BR122019026188 A8 BR 122019026188A8 BR 122019026188 A BR122019026188 A BR 122019026188A BR 122019026188 A BR122019026188 A BR 122019026188A BR 122019026188 A8 BR122019026188 A8 BR 122019026188A8
Authority
BR
Brazil
Prior art keywords
alcoholic
individual
methods
nafld
nash
Prior art date
Application number
BR122019026188A
Other languages
English (en)
Other versions
BR122019026188A2 (pt
BR122019026188B1 (pt
Inventor
Nikrad Malti
G Field Stuart
Alaric Williams Stephen
Original Assignee
Somalogic Inc
Somalogic Operating Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Somalogic Inc, Somalogic Operating Co Inc filed Critical Somalogic Inc
Priority claimed from BR112015021992-6A external-priority patent/BR112015021992B1/pt
Publication of BR122019026188A2 publication Critical patent/BR122019026188A2/pt
Publication of BR122019026188A8 publication Critical patent/BR122019026188A8/pt
Publication of BR122019026188B1 publication Critical patent/BR122019026188B1/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/978—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • G01N2333/98—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/08—Hepato-biliairy disorders other than hepatitis
    • G01N2800/085—Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Abstract

São fornecidos métodos, composições e kits para determinar se um sujeito tem doença hepática gordurosa não alcoólica (DHGNA). Também são fornecidos métodos, composições e kits para determinar se um sujeito tem esteatose não alcoólica. Também são fornecidos métodos, composições e kits para determinar se um sujeito tem esteatohepatite não alcoólica (EHNA).
BR122019026188-1A 2013-03-15 2014-03-10 Métodos para determinar se um indivíduo com esteatose não alcoólica tem esteato-hepatite não alcoólica e para monitorar um indivíduo com esteatose não alcoólica para o desenvolvimento de nash BR122019026188B1 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361787967P 2013-03-15 2013-03-15
US61/787,967 2013-03-15
PCT/US2014/022547 WO2014150198A2 (en) 2013-03-15 2014-03-10 Nonalcoholic fatty liver disease (nafld) and nonalcoholic steatohepatitis (nash) biomarkers and uses thereof
BR112015021992-6A BR112015021992B1 (pt) 2013-03-15 2014-03-10 Método para determinar se um indivíduo tem esteato-hepatite não alcoólica (nash)

Publications (3)

Publication Number Publication Date
BR122019026188A2 BR122019026188A2 (pt) 2017-07-18
BR122019026188A8 true BR122019026188A8 (pt) 2022-10-18
BR122019026188B1 BR122019026188B1 (pt) 2024-01-02

Family

ID=50483498

Family Applications (1)

Application Number Title Priority Date Filing Date
BR122019026188-1A BR122019026188B1 (pt) 2013-03-15 2014-03-10 Métodos para determinar se um indivíduo com esteatose não alcoólica tem esteato-hepatite não alcoólica e para monitorar um indivíduo com esteatose não alcoólica para o desenvolvimento de nash

Country Status (10)

Country Link
US (3) US9612248B2 (pt)
EP (3) EP3660512A1 (pt)
CN (2) CN108957006B (pt)
BR (1) BR122019026188B1 (pt)
DK (1) DK3296747T3 (pt)
ES (2) ES2773999T3 (pt)
HK (1) HK1220251A1 (pt)
MX (1) MX360140B (pt)
WO (1) WO2014150198A2 (pt)
ZA (1) ZA201506441B (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014150198A2 (en) * 2013-03-15 2014-09-25 Somalogic, Inc. Nonalcoholic fatty liver disease (nafld) and nonalcoholic steatohepatitis (nash) biomarkers and uses thereof
EA201791982A1 (ru) 2015-03-09 2020-02-17 Интекрин Терапьютикс, Инк. Способы лечения неалкогольной жировой болезни печени и/или липодистрофии
JP2018518169A (ja) * 2015-06-05 2018-07-12 レグルス セラピューティクス インコーポレイテッド 非アルコール性脂肪肝疾患バイオマーカー
CN116008563A (zh) * 2016-02-08 2023-04-25 私募蛋白质体操作有限公司 非酒精性脂肪肝疾病(nafld)和非酒精性脂肪性肝炎(nash)生物标记及其用途
US20190071795A1 (en) * 2016-03-09 2019-03-07 Molecular Stethoscope, Inc. Methods and systems for detecting tissue conditions
CN107630084A (zh) * 2016-07-18 2018-01-26 昆山德诺瑞尔生物科技有限公司 非酒精性脂肪性肝炎的多基因组合检测试剂盒
JP6893406B2 (ja) * 2016-10-19 2021-06-23 日本化薬株式会社 Ｎａｓｈやｎａｆｌｄの進展度の検査方法及び炎症疾患や癌の検査方法
JP7111322B2 (ja) * 2016-12-02 2022-08-02 国立大学法人 東京大学 線維化関連分子に対する抗体およびその医療応用
CA3058806A1 (en) 2017-04-03 2018-10-11 Coherus Biosciences Inc. Ppar.gamma. agonist for treatment of progressive supranuclear palsy
EP3710831A4 (en) * 2017-11-15 2022-01-12 Beth Israel Deaconess Medical Center, Inc. MARKERS FOR THE DIAGNOSIS AND TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS (NASH) AND ADVANCED HEPATIC FIBROSIS
EP3716986A4 (en) * 2017-12-01 2022-02-09 Cornell University NANOPARTICLES AND SUBSETS OF DISTINCT EXOSOMES FOR CANCER DETECTION AND TREATMENT
WO2020087037A2 (en) * 2018-10-26 2020-04-30 Molecular Stethoscope, Inc. Disease stratification of liver disease and related methods
MX2021009726A (es) 2019-02-14 2021-09-14 Mirvie Inc Metodos y sistemas para determinar un estado relacionado con el embarazo de un sujeto.
CN110786834B (zh) * 2019-12-09 2022-04-05 中电健康云科技有限公司 一种基于舌象特征和bmi指数的脂肪肝预测模型
KR20220140727A (ko) * 2020-02-10 2022-10-18 소마로직 오퍼레이팅 컴퍼니, 인코포레이티드 비알코올성 지방간염 (nash) 바이오마커 및 이의 용도
KR20230097095A (ko) * 2020-10-30 2023-06-30 더 제너럴 하스피탈 코포레이션 간 질환의 평가를 위한 키트, 시약 및 방법
WO2022114887A1 (ko) * 2020-11-27 2022-06-02 국립암센터 통합전사체분석 기반 만성 간질환 진단용 복합마커 및 이의 용도
KR20240022539A (ko) * 2021-06-09 2024-02-20 위니베르시트카솔리끄드루뱅 지방간염 및/또는 이의 합병증을 갖거나 발병할 위험을 결정하기 위한 시스템 및 방법

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5580737A (en) 1990-06-11 1996-12-03 Nexstar Pharmaceuticals, Inc. High-affinity nucleic acid ligands that discriminate between theophylline and caffeine
ES2259800T3 (es) 1990-06-11 2006-10-16 Gilead Sciences, Inc. Procedimientos de uso de ligandos de acido nucleico.
US6001577A (en) 1998-06-08 1999-12-14 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex
US5763177A (en) 1990-06-11 1998-06-09 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex
US5660985A (en) 1990-06-11 1997-08-26 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands containing modified nucleotides
US5705337A (en) 1990-06-11 1998-01-06 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: chemi-SELEX
US6458539B1 (en) 1993-09-17 2002-10-01 Somalogic, Inc. Photoselection of nucleic acid ligands
US6242246B1 (en) 1997-12-15 2001-06-05 Somalogic, Inc. Nucleic acid ligand diagnostic Biochip
WO2005000335A2 (en) * 2003-06-02 2005-01-06 Ohio University Use of genes differentially expressed during aging of liver for treatment and diagnosis
WO2007133586A2 (en) 2006-05-08 2007-11-22 Tethys Bioscience, Inc. Systems and methods for developing diagnostic tests based on biomarker information from legacy clinical sample sets
US7855054B2 (en) 2007-01-16 2010-12-21 Somalogic, Inc. Multiplexed analyses of test samples
US7947447B2 (en) 2007-01-16 2011-05-24 Somalogic, Inc. Method for generating aptamers with improved off-rates
WO2008156662A1 (en) * 2007-06-14 2008-12-24 George Mason Intellectual Properties, Inc. Methods of diagnosing non-alcoholic steatohepatitis (nash)
EP2336314A1 (en) 2007-07-17 2011-06-22 Somalogic, Inc. Improved selex and photoselex
ES2394152T3 (es) 2008-07-03 2013-01-22 One Way Liver Genomics, S.L. Huella proteómica para el diagnóstico de la esteatohepatitis no alcohólica (EHNA) y/o esteatosis
US20100124548A1 (en) * 2008-10-29 2010-05-20 University Of Oulu Pharmaceutical product
WO2011054893A2 (en) * 2009-11-05 2011-05-12 Novartis Ag Biomarkers predictive of progression of fibrosis
US20130116150A1 (en) 2010-07-09 2013-05-09 Somalogic, Inc. Lung Cancer Biomarkers and Uses Thereof
AU2011312491B2 (en) 2010-09-27 2015-06-04 Somalogic, Inc. Mesothelioma biomarkers and uses thereof
WO2014074682A1 (en) * 2012-11-07 2014-05-15 Somalogic, Inc. Chronic obstructive pulmonary disease (copd) biomarkers and uses thereof
WO2014150198A2 (en) * 2013-03-15 2014-09-25 Somalogic, Inc. Nonalcoholic fatty liver disease (nafld) and nonalcoholic steatohepatitis (nash) biomarkers and uses thereof

Also Published As

Publication number Publication date
ZA201506441B (en) 2019-07-31
EP3296747A1 (en) 2018-03-21
BR122019026188A2 (pt) 2017-07-18
CN108957006A (zh) 2018-12-07
CN108957006B (zh) 2021-07-27
HK1220251A1 (zh) 2017-04-28
BR122019026188B1 (pt) 2024-01-02
DK3296747T3 (da) 2020-03-30
US20140303018A1 (en) 2014-10-09
BR112015021992A8 (pt) 2022-10-18
EP3296747B1 (en) 2020-01-08
EP2972386B1 (en) 2018-01-10
US9945875B2 (en) 2018-04-17
ES2773999T3 (es) 2020-07-16
EP2972386A2 (en) 2016-01-20
WO2014150198A2 (en) 2014-09-25
WO2014150198A3 (en) 2014-12-18
US20180259537A1 (en) 2018-09-13
US20170227550A1 (en) 2017-08-10
CN105143887A (zh) 2015-12-09
MX360140B (es) 2018-10-24
EP3660512A1 (en) 2020-06-03
CN105143887B (zh) 2018-08-28
BR112015021992A2 (pt) 2017-07-18
US9612248B2 (en) 2017-04-04
MX2015011756A (es) 2016-01-14
ES2662108T3 (es) 2018-04-05
US10359435B2 (en) 2019-07-23

Similar Documents

Publication Publication Date Title
BR122019026188A8 (pt) Métodos para determinar se um indivíduo tem doença hepática gordurosa não alcoólica (nafld), se um indivíduo com esteatose não alcoólica tem esteato-hepatite não alcoólica e para monitorar um indivíduo com esteatose não alcoólica para o desenvolvimento de nash
BR112018014842A2 (pt) biomarcadores de doenças hepática gordurosa não alcoólica (nafld) e esteato-hepatite não alcoólica (nash) e utilização dos mesmos
CR20160199A (es) Terapia combinada con un anticuerpo anti-ang2 y un agonista de cd40
EP4282983A3 (en) Compositions and methods for polynucleotide sequencing
WO2016094839A3 (en) Compositions and methods for performing methylation detection assays
EA201592269A1 (ru) Способы и композиции для снижения иммуносупрессии опухолевыми клетками
IL240183A (en) Non-Alcoholic Obesity Preparation (nafld)
CR20150247A (es) Anticuerpos de antihemaglutinina y métodos de uso
EA201692318A1 (ru) Композиции и способы для ингибирования экспрессии гена альфа-1-антитрипсина
MX2019005082A (es) Composiciones que comprenden 15-ohepa y metodos para usar las mismas.
MX2022002365A (es) Composiciones y metodos relacionados con el diagnostico de cancer de prostata.
WO2014209905A3 (en) Methods and compositions for detecting and diagnosing diseases and conditions
WO2014197835A3 (en) Methods and compositions for the treatment of cancer
BR112015019393A2 (pt) dispositivo de ejeção de fluido
BR112015023387A2 (pt) composições lipídicas de racecodotril
CO7151478A2 (es) Formulaciones estabilizadas que contienen anticuerpos anti-dll4
WO2014124307A3 (en) Targeted theranostics
MX2012012095A (es) Analogos de tiazolidinadiona.
MX2019002579A (es) Composiciones y metodos de uso de depuradores de gamma-cetoaldehido para tratar, evitar o mejorar la enfermedad del higado graso no alcoholico (nafld), nash, ald o condiciones relacionadas al higado.
WO2014169011A3 (en) Methods for treating immune diseases
BR112017014842A2 (pt) composição de agente de formação de imagem, kit de agente de formação de imagem, e, método para preparação de uma composição de agente de formação de imagem
UY34081A (es) Composición farmacéutica que comprende drotaverina
AR098790A1 (es) Terapia combinada con un anticuerpo anti-ang2 y un agonista de cd40
CN302458772S (zh) 门花(六福送宝)
UA99496U (uk) Спосіб експрес-діагностики післяродового ендометриту у корів реактивом бенедикта

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: SOMALOGIC OPERATING CO., INC. (US)

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 10/03/2014, OBSERVADAS AS CONDICOES LEGAIS